# Richard W. Joseph

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-w-joseph/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,942 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 53 |
| i10-index | 143 |
| Last Known Institution | Daiichi Sankyo (United States) |
| OpenAlex ID | https://openalex.org/A5034715033 |
| ORCID iD | https://orcid.org/0000-0001-6102-4661 |
| Works | 282 |

## Researcher papers

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [High response rate to PD-1 blockade in desmoplastic melanomas](https://scholariq.org/papers/high-response-rate-to-pd-1-blockade-in-desmoplastic-melanomas/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Researcher university

- [Daiichi Sankyo (United States)](https://scholariq.org/institutions/daiichi-sankyo-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.